2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors

Klin Padiatr 2017; 229: 147-167 DOI: 10.1055/s-0043-103086The clinical course of neuroblastoma is more heterogeneous than any other malignant disease. Most low-risk patients experience regression after limited or even no chemotherapy. However, more than half of high-risk patients die from disease despite intensive multimodal treatment. Precise patient characterization at diagnosis is key for risk-adapted treatment. The guidelines presented here incorporate results from national and international clinical trials to produce recommendations for diagnosing and treating neuroblastoma patients in German hospitals outside of clinical trials. [...] © Georg Thieme Verlag KG Stuttgart · New YorkArticle in Thieme eJournals: Table of contents  |  Abstract  |  Full text

Source: Klinische Padiatrie - May 30, 2017 Category: Pediatrics Authors: Simon, Thorsten Hero, Barbara Schulte, Johannes H. Deubzer, Hedwig Hundsdoerfer, Patrick von Schweinitz, Dietrich Fuchs, J örg Schmidt, Matthias Prasad, Vikas Krug, Barbara Timmermann, Beate Leuschner, Ivo Fischer, Matthias Langer, Thorsten Astrahantseff Tags: Diagnostic and Treatment Recommendation Source Type: research